HER2 status in residual disease after neoadjuvant treatment might determine sensitivity to trastuzumab emtansine.
作者信息
Altundag Kadri
机构信息
MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey.
出版信息
J BUON. 2019 Jul-Aug;24(4):1736.
PMID:31646835
Abstract
摘要
相似文献
1
2
3
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?曲妥珠单抗-恩杂鲁胺用于HER2阳性转移性乳腺癌：最佳治疗顺序是什么？
Chin Clin Oncol. 2018 Feb;7(1):3. doi: 10.21037/cco.2017.10.08. Epub 2017 Nov 6.
4
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.一名35岁女性，在接受浸润性乳腺癌新辅助化疗后HER2表达发生变化
Oncology (Williston Park). 2018 Jun;32(6):298-302.
5
T-DM1 for residual, invasive, HER2-positive breast cancer.曲妥珠单抗-美坦新偶联物用于残留、浸润性、HER2阳性乳腺癌。
Lancet Oncol. 2019 Jan;20(1):e13. doi: 10.1016/S1470-2045(18)30918-5. Epub 2018 Dec 13.
6
Trastuzumab emtansine for HER2-positive breast cancer.曲妥珠单抗恩美曲妥珠单抗用于治疗HER2阳性乳腺癌。
Lancet Oncol. 2016 Dec;17(12):e528. doi: 10.1016/S1470-2045(16)30589-7. Epub 2016 Nov 18.
7
ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.ASO作者反思：选择患者进行手术消除试验——预测新辅助全身治疗后HER2阳性乳腺癌患者的残余浸润性和原位疾病
Ann Surg Oncol. 2019 Dec;26(Suppl 3):804-805. doi: 10.1245/s10434-019-07943-2. Epub 2019 Oct 25.
8
The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.人表皮生长因子受体2新辅助单克隆抗体（曲妥珠单抗）治疗对乳腺导管原位癌的影响。
Histopathology. 2017 May;70(6):1009-1011. doi: 10.1111/his.13145. Epub 2017 Feb 7.
9
The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.癌胚抗原相关细胞黏附分子 6 与人表皮生长因子受体 2 的相互作用与曲妥珠单抗治疗乳腺癌的疗效相关。
J Pathol. 2018 Nov;246(3):379-389. doi: 10.1002/path.5148. Epub 2018 Oct 4.
10
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.在 MARIANNE 研究中，曲妥珠单抗-美坦新偶联物±帕妥珠单抗对比曲妥珠单抗联合紫杉烷类用于 HER2 阳性晚期乳腺癌的 III 期研究中，肿瘤标志物与疗效的关系。
BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0.
Zotero 插件